• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts
    • MPR: Breakthrough Products Series
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Job Board
    • Leadership in Medtech
    • Manufacturer Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
    • DeviceTalks
  • Coronavirus: Live updates

Kala Pharmaceuticals

Kala Pharmaceuticals wins FDA nod for dry eye treatment

October 28, 2020 By Sean Whooley

Kala Pharmaceuticals announced that it received FDA approval for its Eysuvis treatment for signs and symptoms of dry eye disease. Watertown, Mass.-based Kala’s Eysuvis loteprednol etabonate ophthalmic suspension uses the company’s Ampplify mucus-penetrating particle (MPP) drug delivery technology to enhance the penetration of loteprednol etabonate (LE) into target tissue on the ocular surface, according to […]

Filed Under: Drug-Device Combinations, Food & Drug Administration (FDA), Optical/Ophthalmic, Regulatory/Compliance Tagged With: FDA, Kala Pharmaceuticals

Kala seeks FDA nod for dry eye disease drug

October 16, 2018 By Sarah Faulkner

Kala Pharmaceuticals (NSDQ:KALA) said today that it submitted a new drug application to the FDA for its KPI-121 0.25% topical product designed for patients with dry eye disease. The Waltham, Mass.-based company noted that roughly 33 million people in the U.S. have dry eye disease and nearly 90% of those patients experience flares in symptoms. Kala […]

Filed Under: Clinical Trials, Drug-Device Combinations, Food & Drug Administration (FDA), Optical/Ophthalmic, Pharmaceutical, Regulatory/Compliance, Wall Street Beat Tagged With: Kala Pharmaceuticals

Kala Pharmaceuticals prices $62m public offering

October 3, 2018 By Sarah Faulkner

Kala Pharmaceuticals (NSDQ:KALA) priced an underwritten public offering of 7,500,000 shares of common stock at $8.25 per share. The Waltham, Mass.-based company is expected to reel in nearly $62 million in proceeds from the offering. Kala Pharmaceuticals also gave underwriters a 30-day option to buy an additional 1,125,000 shares of common stock at $8.25 apiece. Get the full story […]

Filed Under: Funding Roundup, Optical/Ophthalmic, Pharmaceutical, Wall Street Beat Tagged With: Kala Pharmaceuticals

Kala Pharma wins FDA nod for twice-daily ocular corticosteroid

August 24, 2018 By Nancy Crotti

The FDA has approved Kala Pharmaceuticals’ (NASDAQ:KALA) Inveltys to treat post-operative inflammation and pain following ocular surgery. Inveltys is the first twice-daily (BID) ocular corticosteroid approved for this indication, according to the Waltham, Mass. company. While corticosteroids are used following ocular surgery to control inflammation and pain, physicians prescribe ocular steroids to achieve a rapid reduction of […]

Filed Under: Clinical Trials, Food & Drug Administration (FDA), Optical/Ophthalmic, Pain Management, Pharmaceutical Tagged With: FDA, Kala Pharmaceuticals

Anika CEO retires after two decades; president assumes corner office | Personnel Moves – March 13, 2018

March 13, 2018 By Sarah Faulkner

Anika Therapeutics (NSDQ:ANIK) announced this month that CEO Charles Sherwood plans to retire after working for Anika for nearly twenty years. Joseph Darling, who has been Anika’s president since July 2017, will take his place in the corner office. Darling has previously served in executive leadership roles across an array of medtech companies like Abbott (NYSE:ABT), Baxter (NYSE:BAX) and Smith & Nephew (NYSE:SNN). […]

Filed Under: Drug-Device Combinations, Pharmaceutical, Wall Street Beat Tagged With: alucentmedical, Anika Therapeutics Inc., BioTime, BrainStorm Cell Therapeutics Inc., Kala Pharmaceuticals, medherant, milestonescientific, pertinaxpharma, West Pharmaceutical Services Inc.

Kala Pharma reveals mixed Ph3 data for dry eye disease drug

January 5, 2018 By Sarah Faulkner

Kala Pharmaceuticals (NSDQ:KALA) shares dropped -28% today after the company revealed mixed results from two Phase III trials of its dry eye disease drug, KPI-121. In its Stride 1 trial, the company’s drug met statistical significance for the primary endpoint of conjuctival hyperemia change from baseline to day 15, as well as the primary endpoint of […]

Filed Under: Clinical Trials, Optical/Ophthalmic, Pharmaceutical, Wall Street Beat Tagged With: Kala Pharmaceuticals

Kala Pharmaceuticals taps biopharma exec as chief operating officer | Personnel Moves – Nov. 27, 2017

November 27, 2017 By Sarah Faulkner

Kala Pharmaceuticals (NSDQ:KALA) this month expanded its team of C-suite executives, naming Todd Bazemore as chief operating officer. Bazemore has spent more than 20 years in the biopharmaceutical industry, most recently working as EVP and COO for Santhera Pharmaceuticals. He has also spent time at Dyax Corp., Sunovion Pharmaceuticals, and Muro Pharmaceuticals. “We welcome Todd to […]

Filed Under: Drug-Device Combinations, Pharmaceutical, Wall Street Beat Tagged With: Biogen, Eli Lilly & Co., Gamida Cell, Kala Pharmaceuticals, Personnel Moves, pertinaxpharma, Pfizer

Kala nabs $104m in IPO

July 26, 2017 By Sarah Faulkner

Kala Pharmaceuticals (NSDQ:KALA) said today that it closed its initial public offering of 6.9 million shares of common stock. The Waltham, Mass.-based company priced its public offering at $15.00 per share, granting underwriters an option to buy up to 900,000 additional shares. The exercise of this option brought the proceeds of its IPO up from $90 […]

Filed Under: Funding Roundup, Initial Public Offering (IPO), Optical/Ophthalmic, Pharmaceutical, Wall Street Beat Tagged With: Kala Pharmaceuticals

Kala Pharmaceuticals prices $90m IPO

July 20, 2017 By Sarah Faulkner

Kala Pharmaceuticals (NSDQ:KALA) today priced its initial public offering of 6 million shares of common stock at $15.00 apiece. The IPO is slated to bring in nearly $90 million for the Waltham, Mass.-based company. The offering, which is expected to close on July 25, includes a 30-day option for underwriters to buy up to 900,000 additional shares of […]

Filed Under: Drug-Device Combinations, Funding Roundup, Initial Public Offering (IPO), Optical/Ophthalmic, Pharmaceutical, Wall Street Beat Tagged With: Kala Pharmaceuticals

Kala touts Phase III data for nanoparticle ophthalmic suspension

May 1, 2017 By Sarah Faulkner

Kala Pharmaceuticals touted data today from a Phase III trial of its nanoparticle formulation of loteprednol etabonate as a treatment for inflammation and pain in cataract surgery patients. The KPI-121 1% suspension met both primary efficacy endpoints and secondary endpoints and was well tolerated by the trial’s participants. The Waltham, Mass.-based company’s KPI-121 uses Kala’s mucus-penetrating […]

Filed Under: Clinical Trials, Drug-Device Combinations, Optical/Ophthalmic, Pharmaceutical Tagged With: Kala Pharmaceuticals

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Tweets by @MassDevice
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion

MASSDEVICE

Subscribe to MassDevice
Advertise with us
About
Contact us

Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2021 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS